Surgery Journal Club

1. Surgery Journal Club Breast-Cancer Related Lymphedema :A Review of Procedure-Specific Incidence Rates , Clinical Assessment Aids , Treatment Paradigms & Risk ReductionThe Breast Journal , July-August 2012 , Nashville Breast Cancer , Tennessee By : Ahmad Zahmatkesh Mohammadreza Nazemian

2. Introduction • As the number of women who are long term survivors of breast cancer increases , chronic toxicities such as breast cancer related lymphedema ( BCRL ) gain importance • Purpose of this Review : Summarize the latest studies addressing BCRL in order to provide patients and health care providers with optimal recommendations

3. Rates of BCRL • Well documented in older randomized breast cancer treatment trials exemplified by NSABP B-04 Trial : * NSABP : National Surgical Adjuvant Breast & Bowel Project

4. Rates of BCRL • Recent data has emerged that rates of BCRL are predicated on the aggressiveness of treatment : • Breast surgical procedure performed • Method of axillary surgery ( Sentinel LN Vs. Axillary LN Dissection ) • Use and extent of adjuvant radiation therapy • Use of adjuvant chemotherapy

5. Rates of BCRL • In a Series of over 3000 patients which evaluated for incidence of BCRL after breast conservation (BC) via survey were :

6. Rates of BCRL • NSABP B-32 Trial demonstrated that rates of BCRL significantly reduced with the use of SLND over ALND , 8% vs. 14% • Coen et al. examined 727 patients who were treated with BCS and WBI with or without regional irradiation and found that rates of BCRL were 2% for tangents alone vs. 9% with regional irradiation • Norman et al. found that patients receiving chemotherapy had an increased risk of developing BCRL with a HR of 1.46

7. Rates of BCRL • Table 1 - Rates of BCRL by Loco-Regional Therapy

8. Diagnosis of Lymphedema • With Traditional studies the diagnosis of BCRL in the subclinical phase of disease remain limited and often diagnosed after development of significant BCRL • Improvements in BCRL diagnostic modalities decreased the number of women suffering with the long term complications

9. Diagnosis of Lymphedema • Traditional Studies : • Arm circumference measurement : • Simple • Lack of standardized measuring points and definition of BCRL , Intra and Inter-Observer variability • Water displacement : • Lacks Sensitivity • Self-assessment

10. Diagnosis of Lymphedema • New detection techniques : • Bioimpedance Spectroscopy ( BIS ) • Standardized cut-off point • Increased sensitivity and detect BCRL 4 months earlier >> Potential for subclinical detection • Optoelectric Perometry • Increased Sensitivity and Decreased variability

11. Treatment of Lymphedema • BCRL management involves : • Severity of volume accumulation • Severity of Symptoms • Acute vs. Chronic nature of disease

12. Treatment of Lymphedema • Treatments include : • Compression therapy : • The efficacy remains controversial • Techniques and Devices : • Compression bandages or garments • Gradient compression devices • Pneumatic compression devices • Multi-modality ( ie., Complex Decongestive physiotherapy ) • Pharmacotherapy : • Benzopyrones : • Decrease fluid volume , Improvement of Subjective Pain , Tightness and Acute inflammation • Diuretics • Selenium

13. Treatment of Lymphedema • Complex Decongestive physiotherapy • Utilized for more advanced BCRL • Includes : Compression , MLD , Basic Skin care and Exercise • Administered by well-trained therapists • Phase I : Outpatient / Multi-week program of MLD , Short-stretch compression bandaging , Exercise and Proper skin-nail care and preparing patient for phase II • Phase II : At Home / Entails Skin care , Exercise , Self-massage and Use of compression • The Efficacy of CDP has been verified in multiple studies and improved patient’s quality of life as well as decreasing excess arum volume accumulation

14. Risk Reduction • By Eliminating ALND and not adding regional irradiation , the rates of BCRL may be significantly reduced • By Limiting the number of patients receiving regional irradiation further reduction of BCRL would be seen • By Using new techniques that examine genetic markers in tumors and provide recurrence risk scores , the number of patients requiring chemotherapy will likely decrease so developing of BCRL will reduce • Early Diagnosis at the subclinical stages represent a novel and recently tested method to reduce the risk of BCRL

15. Discussion • BCRL is more prevalent than generally appreciated even after less morbid axillary procedures ( including SLND ) are utilized • BCRL can be detected earlier when newer diagnostic interventions are applied to prevent the chronic phase of the disease as well as sequelae including infection , ulceration and disfigurement

16. Discussion • Simple and reproducible assessment aids currently exist and should be used both prior and after local therapies in virtually all “at risk “ patients • Data regarding optimal treatment strategies is limited and controversies do exist but based on the currently available CDP represents a therapeutic modality with significant supporting evidence in patients with clinically detectable BCRL

17. Discussion • Utilization of new diagnostic modalities may facilitate earlier clinician detection and management of BCRL and have the potential to significantly reduce costs associated with the management of BCRL

18. Thanks For Your Attention